Clinical trials · Raleigh–Durham, NC
Follicular Lymphoma clinical trials in Raleigh–Durham
We’re tracking 15 recruiting follicular lymphoma studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Durham, North CarolinaAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Durham, North CarolinaAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Durham, North CarolinaAges 18 years+ - NCT06337318RecruitingPhase 3
Comparing two drugs for low-tumor burden follicular lymphoma
This trial compares a standard drug called rituximab to a newer medicine called mosunetuzumab for people with a slow-growing type of lymphoma that is not causing many symptoms. The goal is to see if mosunetuzumab works better and has fewer side effects.
Durham, North CarolinaAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Durham, North CarolinaAges 18–75 - NCT07634471RecruitingPhase 2/Phase 3
Testing MK-1045 and Rituximab for Untreated Follicular Lymphoma
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Durham, North CarolinaAges 18 years+ - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Durham, North CarolinaAges 18 years+ - NCT06860880Recruiting
Personalized program to fight cancer-related fatigue
This trial tests a personalized supportive care program that combines exercise, nutrition, and coaching to help reduce fatigue in people with certain slow-growing lymphomas. It aims to improve energy and quality of life.
Chapel Hill, North CarolinaAges 18 years+ - NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Chapel Hill, North CarolinaAges 18 years+ - NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Chapel Hill, North CarolinaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chapel Hill, North CarolinaAges Any age - NCT04223765RecruitingPhase 1
Testing a new CAR T-cell treatment for kappa cancers
This Phase 1 trial studies a lab-made immune therapy (CAR T cells) that targets “kappa” markers on certain lymphomas and CLL/SLL. It’s for people whose cancer has come back or didn’t respond to standard treatments, aiming to improve control of the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT06091254RecruitingPhase 3
Comparing odronextamab to standard chemo for untreated follicular lymphoma
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Chapel Hill, North CarolinaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Chapel Hill, North CarolinaAges 13–90
Hear when a new Follicular Lymphoma trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Follicular Lymphoma trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting follicular lymphoma studies listed above.
- Duke University Medical Center · 5 studies
- UNC Lineberger Comprehensive Cancer Center · 4 studies
- Duke University · 2 studies
- University of North Carolina at Chapel Hill · 2 studies
- Duke Cancer Institute
- Massive Bio SYNERGY-AI site
- North Carolina Basnight Cancer Hospital
- North Carolina Cancer Hospital
What taking part in a follicular lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting follicular lymphoma studies in North Carolina.
Common questions
- Are there follicular lymphoma clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 15 recruiting follicular lymphoma studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a follicular lymphoma study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a follicular lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New follicular lymphoma studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.